ETV6-NTRK3 gene fusion positive secretory carcinoma breast in a two year seven-month-old child with metastatic axillary lymph node: a case report and review of literature

Reshma R. Balachandran; Sajid S. Quereshi; Garvit Chitkara; Tanuja Shet; Sudeep Gupta; Omshree Shetty

doi:10.18203/2349-2902.isj20260480

Authors

Reshma R. Balachandran Department of Surgical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India
Sajid S. Quereshi Department of Surgical Oncology, Tata Memorial Hospital and Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India
Garvit Chitkara Breast Surgical Oncology, Nanavati Max Super Speciality Hospital, Mumbai, Maharashtra, India
Tanuja Shet Department of Pathology, Tata Memorial Hospital and Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India
Sudeep Gupta Department of Medical Oncology, Tata Memorial Hospital and Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India
Omshree Shetty Molecular Pathology, Tata Memorial Hospital and Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2349-2902.isj20260480

Keywords:

Breast, Secretory carcinoma, ETV6-NTRK3, Entrectinib

Abstract

Secretory breast carcinoma (SBC) is an exceptionally rare type of breast carcinoma, accounting for less than 0.15% of all breast cancers. Only few cases have been reported in literature and even less with axillary lymph node metastasis and there is emerging application of use of Sentinel Lymph node biopsy (SLNB) or Low axillary sampling to assess the nodal status. There is a lack of consensus regarding the exact management and the role of targeted therapy is evolving. We report a case of SBC in a 2 year 7-month-old child. The child presented with a painless mobile peri areolar lump with blood-stained nipple discharge. She underwent excision biopsy outside followed by wide excision of residual lump with Low axillary sampling of the axilla showing axillary lymph node metastasis in our Centre and was subjected to level III axillary clearance. The tumor showed positivity for Estrogen receptor (ER) and the characteristic translocation, t (12; 15) (p13; q25) that results in the expression of the ETV6-NTRK3 fusion gene. After careful analysis of the case in Multidisciplinary team meeting, the child was started on Tamoxifen due to ER positivity and was decided to avoid use of chemoradiotherapy considering the age and doubtful benefit. Later when the tumour turned out to be positive for the fusion gene, she was started on targeted therapy with Entrectinib. To our knowledge, this is the youngest case reported in literature. The increasing use of targeted agents has been an evolving trend in the management of SBC with successful treatment outcomes. After careful analysis of our case and available literature, we have come to a conclusion that the treatment of choice for SBC should be conservation surgery with SLNB or Low axillary sampling followed by hormonal treatment if hormone responsive and the use of targeted agents. There is no reliable data regarding the role of adjuvant chemotherapy in SBC. Regarding adjuvant Radiotherapy, though it has been used in adults, its use in children should be limited.

Metrics

Metrics Loading ...

References

McDivitt R, Stewart FW. Breast carcinoma in children. JAMA. 1966;195(5):388-90. DOI: https://doi.org/10.1001/jama.1966.03100050096033

Tavassoli F, Norris H. Secretory carcinoma of the breast. Cancer. 1980;45(9):2404-13. DOI: https://doi.org/10.1002/1097-0142(19800501)45:9<2404::AID-CNCR2820450928>3.0.CO;2-8

Krausz T, Jenkins D, Grontoft O, Pollock D, Azzopardi J. Secretory carcinoma of the breast in adults: emphasis on late recurrence and metastasis. Histopathology. 1989;14(1):25-36. DOI: https://doi.org/10.1111/j.1365-2559.1989.tb02111.x

Herz H, Cooke B, Goldstein D. Metastatic secretory breast cancer. Non-responsiveness to chemotherapy: Case report and review of the literature. Ann Oncol. 2000;11(10):1343-8.

Tixier H, Picard A, Guiu S, Coudert B, Loustalot C, Depret O, et al. Long-term recurrence of secretory breast carcinoma with metastatic sentinel lymph nodes. Arch Gynecol Obstet. 2011;283(1):77-8. DOI: https://doi.org/10.1007/s00404-010-1669-9

Eusebi V, Sneige A. Sapino. Secretory carcinoma. WHO Classification of Tumours of the Breast. 2012;71-2.

Karl SR, Ballantine TVN, Zaino R. Juvenile secretory carcinoma of the breast. J Pediatr Surg. 1985;20(4):368-71. DOI: https://doi.org/10.1016/S0022-3468(85)80221-9

Rosen PP, Cranor ML. Secretory carcinoma of the breast. Arch Pathol Lab Med. 1991;115(2):141-4.

Richard G, Hawk JC, Baker AS, Austin RM. Multicentric adult secretory breast carcinoma: DNA flow cytometric findings, prognostic features and review of the world literature. J Surg Oncol. 1990;44(4):238-44. DOI: https://doi.org/10.1002/jso.2930440410

Shui R, Cheng Y, Bai Q, Yang W. Secretory breast carcinoma with a papillary predominant pattern-an uncommon morphology variant. Histopathology. 2017;71(3):488-93.

Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2(5):367-76. DOI: https://doi.org/10.1016/S1535-6108(02)00180-0

Makretsov N, He M, Hayes M, Chia S, Horsman DE, Sorensen PH, et al. A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma. Genes Chromosomes Cancer. 2004;40(2):152-7. DOI: https://doi.org/10.1002/gcc.20028

Castillo MD, Chibon F, Arnould L, Croce S, Ribeiro A, Perot G, et al. Secretory Breast Carcinoma: A histopatologic and genomic spectrum characterized by a joint specific ETV6-NTRK3 gene fusion. Am J Surg Pathol. 2015;39(11):1458-67. DOI: https://doi.org/10.1097/PAS.0000000000000487

Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R, et al. Entrectinib, a Pan-TRK, ROS1 and ALK inhibitor with Activity in Multiple Molecularly Defined Cancer Indications. Mol Cancer Ther. 2016;15(4):628-39. DOI: https://doi.org/10.1158/1535-7163.MCT-15-0758

Lae M, Freneaux P, Sastre-Garau X, Chouchane O, Sigal-Zafrani B, Vincent-Salomon A. Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum. Mod Pathol. 2009;22(2):291-8. DOI: https://doi.org/10.1038/modpathol.2008.184

Anderson P, Albarracin CT, Resetkova E. A large fungating breast mass: secretory carcinoma with apocrine differentiation. Arch Pathol Lab Med. 2006;130(4):50-2. DOI: https://doi.org/10.5858/2006-130-e50-ALFBM

Jacquemier J. Diagnostic pitfalls in mammary pathology. Case 5. Secretory carcinoma. Ann Pathol. 2009;29(3):211-5.

Ozguroglu M, Tascilar K, Ilvan S, Soybir G, Celik V. Secretory carcinoma of the breast. Case report and review of the literature. Oncology. 2005;68(3): 263-8. DOI: https://doi.org/10.1159/000086782

Li DL, Xiao XY, Yang WT, Shui RH, Tu XY, Lu HF, et al. Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature. Mod Pathol. 2012;25(4):567-75. DOI: https://doi.org/10.1038/modpathol.2011.190

Shui RH, Cheng YF, Bai QM, Yang WT. Secretory breast carcinoma with a papillary-predominant pattern: an unusual morphological variant. Histopathology. 2017;71(3):488-93. DOI: https://doi.org/10.1111/his.13232

Herz H, Cooke B, Goldstein D. Metastatic secretory breast cancer. Non-responsiveness to chemotherapy: case report and review of the literature. Ann Oncol. 2000;11(10):1343-7. DOI: https://doi.org/10.1023/A:1008387800525

Cabello C, Alvarenga M, Alvarenga CA, Duarte GM, Pereira PN, Marshall PS. Case report and review of the literature: secretory breast cancer in 13-year-old boy-10 years of follow up. Breast Cancer Res Treat. 2012;133(3):813-20. DOI: https://doi.org/10.1007/s10549-011-1869-4

Drilon A, Siena S, Ignatius Ou SH, Patel M, Ahn MJ, Lee J, et al. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017;7(4):400-9. DOI: https://doi.org/10.1158/2159-8290.CD-16-1237

Ferguson TB, McCarty KS, Filston HC. Juvenile secretory carcinoma and juvenile papillomatosis: diagnosis and treatment. J Pediatr Surg. 1987;22(7):637-9. DOI: https://doi.org/10.1016/S0022-3468(87)80116-1

Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 1997;349(9069):1864-7. DOI: https://doi.org/10.1016/S0140-6736(97)01004-0

Shukla N, Roberts S, Baki M, Mushtaq Q, Goss P, Park B, et al. Successful Targeted Therapy of Refractory Pediatric ETV6-NTRK3 Fusion-Positive Secretory Breast Carcinoma. JCO Precision Oncology. 2017;17:00034. DOI: https://doi.org/10.1200/PO.17.00034

Hong D, Bauer T, Lee J, Dowlati A, Brose M, Farago A, et al. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol. 2019;30(2):325-31. DOI: https://doi.org/10.1093/annonc/mdy539